LV10930B - Eva-based transdermal matrix system for the administration of an oestrogen and/or a progestogen - Google Patents
Eva-based transdermal matrix system for the administration of an oestrogen and/or a progestogen Download PDFInfo
- Publication number
- LV10930B LV10930B LVP-95-77A LV950077A LV10930B LV 10930 B LV10930 B LV 10930B LV 950077 A LV950077 A LV 950077A LV 10930 B LV10930 B LV 10930B
- Authority
- LV
- Latvia
- Prior art keywords
- weight
- parts
- matrix
- pyrrolidone
- component
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title claims abstract description 76
- 239000000583 progesterone congener Substances 0.000 title claims description 30
- 239000000262 estrogen Substances 0.000 title claims description 27
- 229940088597 hormone Drugs 0.000 claims abstract description 40
- 239000005556 hormone Substances 0.000 claims abstract description 40
- 229960003338 crotamiton Drugs 0.000 claims abstract description 16
- 239000000853 adhesive Substances 0.000 claims abstract description 15
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims abstract description 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract description 6
- 229920002678 cellulose Polymers 0.000 claims abstract description 5
- 239000001913 cellulose Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 31
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 24
- -1 aliphatic alcohols Chemical class 0.000 claims description 23
- 239000011248 coating agent Substances 0.000 claims description 23
- 238000000576 coating method Methods 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 21
- 229960005309 estradiol Drugs 0.000 claims description 18
- 229920001577 copolymer Polymers 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 239000008240 homogeneous mixture Substances 0.000 claims description 15
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 13
- 239000005977 Ethylene Substances 0.000 claims description 13
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 12
- 239000001856 Ethyl cellulose Substances 0.000 claims description 12
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 12
- 229920001249 ethyl cellulose Polymers 0.000 claims description 12
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 12
- NJPQAIBZIHNJDO-UHFFFAOYSA-N 1-dodecylpyrrolidin-2-one Chemical compound CCCCCCCCCCCCN1CCCC1=O NJPQAIBZIHNJDO-UHFFFAOYSA-N 0.000 claims description 11
- 229960001652 norethindrone acetate Drugs 0.000 claims description 10
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000000265 homogenisation Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims 5
- 239000000758 substrate Substances 0.000 claims 4
- 229920002101 Chitin Polymers 0.000 claims 1
- 230000001464 adherent effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- ONNSSMGRFLULCC-UHFFFAOYSA-N icosan-9-ol Chemical compound CCCCCCCCCCCC(O)CCCCCCCC ONNSSMGRFLULCC-UHFFFAOYSA-N 0.000 claims 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 abstract description 14
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 abstract description 8
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract description 5
- 150000003953 γ-lactams Chemical class 0.000 abstract description 5
- 239000005038 ethylene vinyl acetate Substances 0.000 abstract description 3
- 230000001076 estrogenic effect Effects 0.000 abstract 1
- 230000001072 progestational effect Effects 0.000 abstract 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 229920003345 Elvax® Polymers 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 229930182833 estradiol Natural products 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 6
- 230000000181 anti-adherent effect Effects 0.000 description 6
- 239000003911 antiadherent Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241001643597 Evas Species 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- 229920003346 Levapren® Polymers 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 229940113120 dipropylene glycol Drugs 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 239000012943 hotmelt Substances 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 229940100640 transdermal system Drugs 0.000 description 2
- ZFPGARUNNKGOBB-UHFFFAOYSA-N 1-Ethyl-2-pyrrolidinone Chemical compound CCN1CCCC1=O ZFPGARUNNKGOBB-UHFFFAOYSA-N 0.000 description 1
- VTHUYJIXSMGYOQ-KOORYGTMSA-N 17-hydroxyprogesterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 VTHUYJIXSMGYOQ-KOORYGTMSA-N 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- OVMUTCNTBVUPAD-UHFFFAOYSA-N CCCCCC(CC)N1C(CCC1)=O Chemical compound CCCCCC(CC)N1C(CCC1)=O OVMUTCNTBVUPAD-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001038 ethylene copolymer Polymers 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 description 1
- 229960000606 medrogestone Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000013148 permeation assay Methods 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229960001424 quinestrol Drugs 0.000 description 1
- PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9403598A FR2717688B1 (fr) | 1994-03-28 | 1994-03-28 | Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV10930A LV10930A (lv) | 1995-12-20 |
| LV10930B true LV10930B (en) | 1996-08-20 |
Family
ID=9461478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-95-77A LV10930B (en) | 1994-03-28 | 1995-03-21 | Eva-based transdermal matrix system for the administration of an oestrogen and/or a progestogen |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5605702A (cs) |
| EP (1) | EP0674900B1 (cs) |
| JP (1) | JPH07309762A (cs) |
| KR (1) | KR950031056A (cs) |
| CN (1) | CN1114587A (cs) |
| AT (1) | ATE173617T1 (cs) |
| AU (1) | AU684601B2 (cs) |
| CA (1) | CA2145579A1 (cs) |
| CZ (1) | CZ289211B6 (cs) |
| DE (1) | DE69506156T2 (cs) |
| DK (1) | DK0674900T3 (cs) |
| ES (1) | ES2127484T3 (cs) |
| FI (1) | FI951425A7 (cs) |
| FR (1) | FR2717688B1 (cs) |
| GR (1) | GR3029402T3 (cs) |
| HU (1) | HU219245B (cs) |
| LV (1) | LV10930B (cs) |
| NO (1) | NO308124B1 (cs) |
| NZ (1) | NZ270810A (cs) |
| PL (1) | PL179022B1 (cs) |
| RU (1) | RU2144818C1 (cs) |
| SK (1) | SK281234B6 (cs) |
| ZA (1) | ZA952468B (cs) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE132751T1 (de) * | 1988-10-27 | 1996-01-15 | Schering Ag | Mittel zur transdermalen applikation enthaltend gestoden |
| KR970706805A (ko) * | 1994-11-18 | 1997-12-01 | 나까토미 히로타카 | 경피흡수첩부제(percutaneously absorbable patch) |
| FR2739032B1 (fr) * | 1995-09-27 | 1997-11-21 | Lhd Lab Hygiene Dietetique | Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base d'eva, procede de preparation et utilisation en therapeutique |
| CA2255891C (en) | 1996-05-24 | 2007-12-04 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing diseases of body passageways |
| US5783208A (en) * | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
| DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
| DE19700913C2 (de) * | 1997-01-14 | 2001-01-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Abgabe von Hormonen |
| IL123813A0 (en) * | 1997-04-11 | 1998-10-30 | Akzo Nobel Nv | Drug delivery system for two or more active substances |
| US6028057A (en) * | 1998-02-19 | 2000-02-22 | Thorn Bioscience, Llc | Regulation of estrus and ovulation in gilts |
| DE19906152B4 (de) * | 1999-02-10 | 2005-02-10 | Jenapharm Gmbh & Co. Kg | Wirkstoffhaltige Laminate für Transdermalsysteme |
| DE10025970C2 (de) * | 2000-05-25 | 2002-04-25 | Lohmann Therapie Syst Lts | Estrogenhaltiges Pflaster mit einem Wirkstoffreservoir auf der Basis von Ethylcellulose und einem Ethylen-Vinylacetat-Vinylpyrrolidon-Copolymer und seine Verwendung |
| DE10118282A1 (de) * | 2001-04-12 | 2002-12-05 | Lohmann Therapie Syst Lts | Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke |
| ATE461681T1 (de) * | 2003-04-29 | 2010-04-15 | Gen Hospital Corp | Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln |
| WO2005035717A2 (en) | 2003-10-03 | 2005-04-21 | Thorn Bioscience, Llc | Process for the synchronization of ovulation for timed breeding without heat detection |
| US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US20070197435A1 (en) * | 2006-02-17 | 2007-08-23 | Webel Stephen K | Process for the synchronization of ovulation for timed breeding without heat detection |
| WO2008088422A2 (en) * | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
| JP5591691B2 (ja) | 2007-05-22 | 2014-09-17 | アムジエン・インコーポレーテツド | 生物活性を有する融合タンパク質を作製するための組成物及び方法 |
| ES2661240T3 (es) | 2009-04-23 | 2018-03-28 | Jbs United Animal Health Ii Llc | Método y composición para sincronizar el momento de inseminación |
| MX2013010497A (es) | 2011-03-16 | 2013-12-16 | Amgen Inc | Inhibidores potentes y selectivos de nav1.3 y nav1.7. |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| JP6285866B2 (ja) | 2011-11-23 | 2018-02-28 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然複合ホルモン補充製剤および療法 |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| CN113398243A (zh) | 2012-11-28 | 2021-09-17 | 联合动物健康第二有限责任公司 | 用于同步小母猪的授精时间的方法 |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| WO2014165277A2 (en) | 2013-03-12 | 2014-10-09 | Amgen Inc. | POTENT AND SELECTIVE INHIBITORS OF Nav1.7 |
| CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| US11318190B2 (en) | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4060084A (en) * | 1976-09-07 | 1977-11-29 | Alza Corporation | Method and therapeutic system for providing chemotherapy transdermally |
| US4752612A (en) * | 1983-07-01 | 1988-06-21 | Nitto Electrical Industrial Co., Ltd. | Method and percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent |
| FR2612785A1 (fr) * | 1987-03-25 | 1988-09-30 | Lhd Lab Hygiene Dietetique | Dispositif auto-adhesif d'administration d'un principe actif par voie percutanee |
| US4994267A (en) * | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Transdermal acrylic multipolymer drug delivery system |
| US5032402A (en) * | 1988-10-27 | 1991-07-16 | The University Of Kentucky Research Foundation | 3-hydroxy-N-methylpyrrolidone and use as transdermal enhancer |
| AU4745390A (en) * | 1988-12-01 | 1990-06-26 | Schering Corporation | Compositions for transdermal delivery of estradiol |
| US5248676A (en) * | 1990-05-17 | 1993-09-28 | Hisamitsu Pharmaceutical Co., Inc. | Estradiol percutaneous administration preparations |
-
1994
- 1994-03-28 FR FR9403598A patent/FR2717688B1/fr not_active Expired - Fee Related
-
1995
- 1995-03-15 DK DK95400573T patent/DK0674900T3/da active
- 1995-03-15 AT AT95400573T patent/ATE173617T1/de not_active IP Right Cessation
- 1995-03-15 EP EP95400573A patent/EP0674900B1/fr not_active Expired - Lifetime
- 1995-03-15 ES ES95400573T patent/ES2127484T3/es not_active Expired - Lifetime
- 1995-03-15 DE DE69506156T patent/DE69506156T2/de not_active Expired - Fee Related
- 1995-03-21 LV LVP-95-77A patent/LV10930B/en unknown
- 1995-03-21 AU AU14979/95A patent/AU684601B2/en not_active Ceased
- 1995-03-24 NO NO951125A patent/NO308124B1/no not_active IP Right Cessation
- 1995-03-24 FI FI951425A patent/FI951425A7/fi unknown
- 1995-03-27 CA CA002145579A patent/CA2145579A1/en not_active Abandoned
- 1995-03-27 ZA ZA952468A patent/ZA952468B/xx unknown
- 1995-03-27 NZ NZ270810A patent/NZ270810A/en unknown
- 1995-03-27 SK SK391-95A patent/SK281234B6/sk unknown
- 1995-03-27 CZ CZ1995768A patent/CZ289211B6/cs not_active IP Right Cessation
- 1995-03-27 PL PL95307889A patent/PL179022B1/pl unknown
- 1995-03-27 HU HU9500881A patent/HU219245B/hu not_active IP Right Cessation
- 1995-03-27 RU RU95104224A patent/RU2144818C1/ru active
- 1995-03-28 JP JP7069472A patent/JPH07309762A/ja active Pending
- 1995-03-28 CN CN95103765A patent/CN1114587A/zh active Pending
- 1995-03-28 US US08/413,208 patent/US5605702A/en not_active Expired - Fee Related
- 1995-03-28 KR KR1019950006674A patent/KR950031056A/ko not_active Withdrawn
-
1999
- 1999-02-15 GR GR990400485T patent/GR3029402T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2144818C1 (ru) | 2000-01-27 |
| JPH07309762A (ja) | 1995-11-28 |
| ES2127484T3 (es) | 1999-04-16 |
| US5605702A (en) | 1997-02-25 |
| GR3029402T3 (en) | 1999-05-28 |
| FI951425A0 (fi) | 1995-03-24 |
| AU684601B2 (en) | 1997-12-18 |
| NO308124B1 (no) | 2000-07-31 |
| HU9500881D0 (en) | 1995-05-29 |
| HUT75237A (en) | 1997-05-28 |
| SK281234B6 (sk) | 2001-01-18 |
| NO951125D0 (no) | 1995-03-24 |
| NZ270810A (en) | 1996-05-28 |
| FR2717688A1 (fr) | 1995-09-29 |
| ZA952468B (en) | 1995-12-19 |
| ATE173617T1 (de) | 1998-12-15 |
| PL179022B1 (en) | 2000-07-31 |
| DK0674900T3 (da) | 1999-06-23 |
| NO951125L (no) | 1995-09-29 |
| PL307889A1 (en) | 1995-10-02 |
| DE69506156D1 (de) | 1999-01-07 |
| FR2717688B1 (fr) | 1996-07-05 |
| CA2145579A1 (en) | 1995-09-29 |
| EP0674900A1 (fr) | 1995-10-04 |
| FI951425A7 (fi) | 1995-09-29 |
| HU219245B (en) | 2001-03-28 |
| SK39195A3 (en) | 1995-10-11 |
| AU1497995A (en) | 1995-10-05 |
| LV10930A (lv) | 1995-12-20 |
| CZ76895A3 (en) | 1995-10-18 |
| KR950031056A (ko) | 1995-12-18 |
| DE69506156T2 (de) | 1999-07-22 |
| EP0674900B1 (fr) | 1998-11-25 |
| CN1114587A (zh) | 1996-01-10 |
| CZ289211B6 (cs) | 2001-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5605702A (en) | Eva-based transdermal matrix system for the administration of an estrogen and/or a progestogen | |
| US5580572A (en) | Styrene-isoprene-styrene copolymer-based transdermal matrix system for the administration of an oestrogen and/or a progestogen | |
| US6007835A (en) | Transdermal matrix system | |
| AU702542B2 (en) | Transdermal matrix system | |
| US5783208A (en) | Transdermal drug delivery matrix for coadministering estradiol and another steroid | |
| US5554381A (en) | Low flux matrix system for delivering potent drugs transdermally | |
| US5200190A (en) | Percutaneous pharmaceutical preparation | |
| RU95104224A (ru) | Самоклеющаяся трансдермальная матричная система на основе этиленвинилацетата для введения в организм эстогена и/или прогестогена и способы ее получения | |
| CA2208374A1 (en) | Transdermal system for the simultaneous delivery of a number of active principles | |
| MXPA98002327A (en) | Transderm matrix system | |
| MXPA97004527A (en) | Transdermic system of administration simultaneade various principles acti |